Young medical personal people

When budgets are tight, there is an obvious pressure to focus on the upfront price of medical technology. But the cheapest option at the point of purchase may not always offer the best value over its lifetime. How a product affects patients and staff, how well it works in practice, and the costs and efficiencies it creates elsewhere can all matter.

Value based procurement (VBP) aims to bring these wider considerations into procurement decisions across the NHS. The Department of Health and Social Care (DHSC)’s Value Based Procurement National Standard Guidance for Medical Technology (MedTech) was developed to help NHS organisations put this approach into practice. Our evaluation of the pilot of the draft Guidance (pre-publication) found strong support for the approach and highlighted important lessons for its wider adoption.

The draft Guidance was piloted with 13 NHS trust sites, alongside two national procurement framework providers, between September 2025 and March 2026. We spoke to procurement, clinical and supplier staff from four pilot locations, including people who had used the Guidance in live procurement exercises. We also gathered feedback from national framework procurement staff and supported DHSC to engage with industry stakeholders about our findings.

 

What did we find?

Participants were positive about the potential for value based procurement to support more balanced decision-making by considering patient and staff outcomes, operational efficiency and longer-term costs alongside upfront price.

Those who had applied the draft Guidance found it clear and practical. They valued the flexibility to tailor the evaluation criteria to individual procurement exercises, including how different domains of value were weighted. They also found the example questions and other resources useful guides for practical application. Together, this provided a structured way to bring clinical, operational and financial perspectives into the decision-making process.

Participants thought that the new approach would be particularly valuable for larger, more complex MedTech procurements, where decisions can have significant financial and patient implications. In one pilot, staff considered the higher upfront costs of heart-lung machines against wider, longer-term benefits. The selected system offered improved safety features and integrated monitoring, which reduced additional consumable costs and enhanced clinical performance.

 

What could affect wider adoption?

Participants felt that the challenge for NHS organisations was not simply understanding the Guidance but creating the conditions to apply it consistently in practice.

They pointed to short-term financial pressures, which could make it harder to justify products where costs and benefits fell to different stakeholders or where benefits emerged over a longer period. They also highlighted gaps in the availability and consistency of data, challenges in assessing and validating evidence, and variation in how clinical and procurement teams worked together.

 

Why is this important?

Addressing these challenges will require more than changes to procurement processes alone. Participants highlighted the importance of raising awareness, strengthening multidisciplinary working and building skills in areas such as assessing evidence and developing value based business cases.

Our recommendations therefore focused on practical training and support, clearer application across different procurement contexts, and working with system partners on wider financial, data and evidence challenges.

As the Guidance is adopted more widely following its publication in June 2026, there is an opportunity to build on these findings and strengthen the evidence on how value based procurement works in practice. We are continuing to support DHSC with monitoring, evaluation and learning as more organisations put the Guidance into practice. This gives us an opportunity to explore not only what helps VBP become embedded, but how organisations make difficult choices when different aspects of value point in different directions, particularly when budgets are under pressure, and what this means for procurement decisions and outcomes.